We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men (NePlaM3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00696748
Recruitment Status : Unknown
Verified June 2008 by Russian Academy of Medical Sciences.
Recruitment status was:  Recruiting
First Posted : June 13, 2008
Last Update Posted : June 13, 2008
Information provided by:

Study Description
Brief Summary:
The objective of the study is to assess the effect of the testosterone therapy on the body composition, lipid and glucose metabolism, inflammatory markers in patients with metabolic syndrome and hypogonadism.

Condition or disease Intervention/treatment Phase
Metabolic Syndrome Hypogonadism Drug: Nebido (testosterone undecanoate) Drug: Placebo Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study With Open-Label Follow-up to Investigate the Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men
Study Start Date : October 2005
Estimated Primary Completion Date : January 2009
Estimated Study Completion Date : December 2010

Arms and Interventions

Arm Intervention/treatment
Active Comparator: 1
Men receiving Nebido
Drug: Nebido (testosterone undecanoate)
Nebido (testosterone undecanoate) intramuscular 4 ml by scheme
Placebo Comparator: 2
Men receiving Placebo
Drug: Placebo
Placebo 4 mL intramuscular

Outcome Measures

Primary Outcome Measures :
  1. waist-to-hip ratio [ Time Frame: 3 years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   35 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • A signed informed consent to participate in the study
  • Men aged 35 to 70 with testosterone levels below 12 nmol/L or free testosterone below 225 pmol/L
  • Presence of the metabolic syndrome according to the IDF definition

Exclusion Criteria:

  • Patients under 35 or above 70 years.
  • Participation in any clinical study within 30 days before the first injection of the drug
  • Simultaneous participation in another clinical study
  • Incapable subjects as well as prisoners
  • Suspicion of a serious organic or mental disease according to medical history and/or clinical examination
  • Prostate cancer, breast cancer or suspicion thereof
  • Presence or history of hepatic tumors
  • Acute or chronic hepatic disease
  • Presence of renal diseases with renal failure
  • Changes in biochemical or hematological laboratory values in spite of lack of clinical manifestations, in the investigator's opinion
  • Suspected lack of the patient's compliance
  • Hypersensitivity to the active substance
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00696748

Contact: Svetlana Kalinchenko, PhD +70951244301 kalinchenko@list.ru
Contact: Yuliya Tishova +79032213276 yulya_tishova@mail.ru

Russian Federation
Scientific Centre for Endocrinology RAMS Recruiting
Moscow, Russian Federation, 117136
Contact: Svetlana Kalinchenko, PhD    +7(095)1244301    kalinchenko@list.ru   
Contact: Yuliya Tishova, PhDstudent    +79032213276    yulya_tishova@mail.ru   
Sub-Investigator: Tishova Yulya, PhD student         
Sponsors and Collaborators
Russian Academy of Medical Sciences
Principal Investigator: Svetlana Kalinchenko, PhD Scientific Center for Endocrinology, Russia
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Svetlana Kalinchenko, Russian Research Center for Endocrinology
ClinicalTrials.gov Identifier: NCT00696748     History of Changes
Other Study ID Numbers: U00006KO
First Posted: June 13, 2008    Key Record Dates
Last Update Posted: June 13, 2008
Last Verified: June 2008

Keywords provided by Russian Academy of Medical Sciences:
metabolic syndrome
testosterone undecanoate

Additional relevant MeSH terms:
Metabolic Syndrome X
Pathologic Processes
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Gonadal Disorders
Endocrine System Diseases
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents